Before Hologic’s 3D digital mammography system can become a commercial product on the U.S. market, the company must develop a program to train physicians on how to interpret this new kind of mammogram.
Before Hologic’s 3D digital mammography system can become a commercial product on the U.S. market, the company must develop a program to train physicians on how to interpret this new kind of mammogram.
“It is digital mammography, so it’s nothing that new,” said Arthur Friedman, a Hologic senior vice president in charge of regulatory, clinical, and quality issues. “But there are slight differences.”
When interpreting conventional digital mammography, radiologists mentally “triangulate” 2D images, said Dr. Emily Conant, a professor of radiology at the University of Pennsylvania Medical Center in Philadelphia.
“Tomosynthesis allows us to scroll through the breast to see in-plane imaging at various depths,” Conant said. “With this, we can find lesions that potentially we couldn’t see before, or explain away pseudolesions that would otherwise lead to false positives.”
But lesions seen in 3D look different, she said, than those in 2D. That’s where the vendor training program will come in. Hologic has already done two studies looking into how physicians should be trained to interpret these images, Friedman said.
September’s unanimous vote by the FDA’s Radiological Devices Panel in favor of Selenia Dimensions paved the way for the system to be commercialized in the U.S. The training program-and only a few “housekeeping” issues-remain to be resolved, Friedman said. If all goes according to plan, Hologic’s 3D digital mammography system could be on the U.S. market within six months.
Early adopters will have a familiar base to work from. Breast tomosynthesis will complement, not replace, 2D digital mammography. Hologic’s regulatory submission to the FDA is based on data from multicenter clinical trials indicating that cancer is easier to spot when interpreting a combination of 3D and 2D views than when looking at 2D images alone. The combination also promises to reduce recall rates.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.